» Articles » PMID: 31426706

Body Mass Index and Risk of Prostate Volume, International Prostate Symptom Score, Maximum Urinary Flow Rate, and Post-Void Residual in Benign Prostatic Hyperplasia Patients

Overview
Date 2019 Aug 21
PMID 31426706
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to evaluate association between body mass index (BMI) and prostate volume (PV), international prostate symptom scores (IPSS), maximum urinary flow rate (), and post-void residual (PVR) of Chinese benign prostatic hyperplasia (BPH) patients. All newly diagnosed BPH patients between September 2016 and August 2018 were selected and 788 patients were included. According to BMI, the patients were categorized into four groups, while according to PV, IPSS, , and PVR, they were categorized into two groups based on clinical significant cutoffs. Univariable and multivariable logistic regressions and a restricted cubic spline (RCS) were applied to explore the relationship of BMI with categorical PV, IPSS, , and PVR. Compared with normal BMI, obesity presented significant association with increased risk of larger PV (>80 ml) in both unadjusted and adjusted models (unadjusted odds ratio [OR] = 1.772, 95% CI [1.201, 2.614], = .004; adjusted OR = 1.912, 95% CI [1.212, 3.017], = .005); however, underweight or overweight did not present a significant connection with such risk. No significant effect was identified for BMI on IPSS, , or PVR in either unadjusted or adjusted model. Nonlinear test including BMI using RCS and adjusting for confounders showed no significance ( > .05); however, a significant linear relationship was ascertained between BMI and the risk of larger PV ( < .001). In conclusion, there was a significant linear association between BMI and the risk of larger PV in BPH patients. Hence, this suggests urologists should consider both BMI and PV when providing surgical treatment for BPH patients.

Citing Articles

Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035.

Wei H, Zhu C, Huang Q, Yang J, Li Y, Zhang Y BMC Urol. 2025; 25(1):34.

PMID: 39972318 PMC: 11837592. DOI: 10.1186/s12894-025-01715-9.


The Correlation Between Body Mass Index and Prostate Volume: A Retrospective Analysis of Pre and Postoperative Measurements in Prostate Cancer Patients.

Barone B, Amicuzi U, Massanova M, Napolitano L, Reccia P, Mirto B Prostate. 2024; 85(5):433-442.

PMID: 39716024 PMC: 11848972. DOI: 10.1002/pros.24845.


Impact of Obesity on Clinical Presentation and Surgical Outcomes in Patients with Benign Prostate Hyperplasia Receiving Greenlight Laser Prostatectomy.

Chen P, Chang R, Wang H, Chang Y, Liu C, Huang L Clin Interv Aging. 2024; 19:2071-2083.

PMID: 39678145 PMC: 11645433. DOI: 10.2147/CIA.S472579.


Correlation between Transabdominal Sonographic Prostate Volume and Anthropometric Parameters.

Udo C, Robinson E, Ijeruh O, Nwankwo N J Med Ultrasound. 2023; 30(4):261-265.

PMID: 36844769 PMC: 9944824. DOI: 10.4103/jmu.jmu_183_21.


Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia.

Abotsi E, Adanu K, Bansah E Afr J Prim Health Care Fam Med. 2022; 14(1):e1-e6.

PMID: 36546488 PMC: 9772733. DOI: 10.4102/phcfm.v14i1.3736.


References
1.
Parikh N, Pencina M, Wang T, Lanier K, Fox C, DAgostino R . Increasing trends in incidence of overweight and obesity over 5 decades. Am J Med. 2007; 120(3):242-50. DOI: 10.1016/j.amjmed.2006.06.004. View

2.
Rundle A, Richards C, Neslund-Dudas C, Tang D, Rybicki B . Neighborhood socioeconomic status modifies the association between individual smoking status and PAH-DNA adduct levels in prostate tissue. Environ Mol Mutagen. 2012; 53(5):384-91. PMC: 3600639. DOI: 10.1002/em.21693. View

3.
Ogilvie R, Patel S . The epidemiology of sleep and obesity. Sleep Health. 2017; 3(5):383-388. PMC: 5714285. DOI: 10.1016/j.sleh.2017.07.013. View

4.
Su X, Zeng X, Fang C, Liu T, Wang X . Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis. Oncotarget. 2017; 8(20):33953-33960. PMC: 5464925. DOI: 10.18632/oncotarget.15424. View

5.
Dias J . Benign prostatic hyperplasia: clinical manifestations and evaluation. Tech Vasc Interv Radiol. 2012; 15(4):265-9. DOI: 10.1053/j.tvir.2012.09.007. View